Abzena Expands GMP Potency Testing
Abzena expands GMP cell-based potency assays, enhancing bioassay services at UK and US facilities.
Abzena, a leading CDMO + CRO, has expanded its early and late-phase analytical services to include GMP cell-based potency assays at its Cambridge, UK, and San Diego, CA facilities. This addition enhances its bioassay offerings, enabling faster, more reliable data critical for biopharmaceutical development, including ADC cytotoxicity and GMP product release testing.
The move supports developers in optimizing strategies, meeting regulatory needs, and advancing drug programs efficiently. Abzena remains committed to delivering end-to-end analytical solutions to drive success from discovery through commercialization.
My international experience as a researcher in Taiwan for three years has equipped me with a global perspective, enabling me to create content that resonates with an international audience.
Altro da Pharma News
Tutti gli articoli →
Medicus Pharma presenta all’FDA il protocollo di fase 2b/3 per Teverelix
Fresenius Kabi Riceve una Lettera di Richiamo dalla FDA dopo Fallimenti nelle Indagini sul Processo Asettico presso lo Stabilimento di Melrose Park
Discussion